Indication
Pseudoxanthoma elasticum
3 clinical trials
2 products
Clinical trial
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period in Adults With ABCC6 Deficiency Manifesting as Pseudoxanthoma Elasticum (PXE)Status: Active (not recruiting), Estimated PCD: 2023-11-07
Product
INZ-701Product
DS-1211bClinical trial
A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma ElasticumStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
The ADAPT Study: An Open-label, Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyStatus: Not yet recruiting, Estimated PCD: 2030-11-01